283 related articles for article (PubMed ID: 28818671)
1. Incidence and risk of cardiotoxicity in cancer patients treated with targeted therapies.
Santoni M; Guerra F; Conti A; Lucarelli A; Rinaldi S; Belvederesi L; Capucci A; Berardi R
Cancer Treat Rev; 2017 Sep; 59():123-131. PubMed ID: 28818671
[TBL] [Abstract][Full Text] [Related]
2. Does the addition of drugs targeting the vascular endothelial growth factor pathway to first-line chemotherapy increase complete response? A meta-analysis of randomized clinical trials.
Li Y; Liang XY; Yue YQ; Sheng L; Liu JK; Wang ZY; Chen G
Tumour Biol; 2016 May; 37(5):6297-306. PubMed ID: 26619847
[TBL] [Abstract][Full Text] [Related]
3. Risk of pruritus in cancer patients treated with biological therapies: A systematic review and meta-analysis of clinical trials.
Santoni M; Conti A; Andrikou K; Bittoni A; Lanese A; Pistelli M; Pantano F; Vincenzi B; Armento G; Massari F; Tonini G; Cascinu S; Santini D
Crit Rev Oncol Hematol; 2015 Nov; 96(2):206-19. PubMed ID: 26070625
[TBL] [Abstract][Full Text] [Related]
4. Risk of Hyponatraemia in Cancer Patients Treated with Targeted Therapies: A Systematic Review and Meta-Analysis of Clinical Trials.
Berardi R; Santoni M; Rinaldi S; Nunzi E; Smerilli A; Caramanti M; Morgese F; Torniai M; Savini A; Fiordoliva I; Onofri A; Pistelli M; Taccaliti A; Cascinu S
PLoS One; 2016; 11(5):e0152079. PubMed ID: 27167519
[TBL] [Abstract][Full Text] [Related]
5. Risk of high-grade bleeding in patients with cancer treated with bevacizumab: a meta-analysis of randomized controlled trials.
Hang XF; Xu WS; Wang JX; Wang L; Xin HG; Zhang RQ; Ni W
Eur J Clin Pharmacol; 2011 Jun; 67(6):613-23. PubMed ID: 21243343
[TBL] [Abstract][Full Text] [Related]
6. Incidence and risk of hypertension associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a comprehensive network meta-analysis of 72 randomized controlled trials involving 30013 patients.
Liu B; Ding F; Liu Y; Xiong G; Lin T; He D; Zhang Y; Zhang D; Wei G
Oncotarget; 2016 Oct; 7(41):67661-67673. PubMed ID: 27602778
[TBL] [Abstract][Full Text] [Related]
7. Risk of fatigue in cancer patients receiving anti-EGFR monoclonal antibodies: results from a systematic review and meta-analysis of randomized controlled trial.
Zhu J; Zhao W; Liang D; Li G; Qiu K; Wu J; Li J
Int J Clin Oncol; 2018 Apr; 23(2):389-399. PubMed ID: 29181651
[TBL] [Abstract][Full Text] [Related]
8. Hemorrhagic events in cancer patients treated with aflibercept: a meta-analysis.
Peng L; Bu Z; Zhou Y; Ye X; Liu J; Zhao Q
Tumour Biol; 2014 Sep; 35(9):9419-27. PubMed ID: 24957040
[TBL] [Abstract][Full Text] [Related]
9. Incidence and risk of severe infections associated with aflibercept in cancer patients: a systematic review and meta-analysis.
Zhang X; Ran Y; Shao Y; Wang K; Zhu Y
Br J Clin Pharmacol; 2016 Jan; 81(1):33-40. PubMed ID: 26331893
[TBL] [Abstract][Full Text] [Related]
10. Targeted therapy for solid tumors and risk of hypertension: a meta-analysis of 68077 patients from 93 phase III studies.
Santoni M; Conti A; Massari F; Di Nunno V; Faloppi L; Galizia E; Morbiducci J; Piva F; Buti S; Iacovelli R; Ferretti B; Cimadamore A; Scarpelli M; Lopez-Beltran A; Cheng L; Battelli N; Montironi R
Expert Rev Cardiovasc Ther; 2019 Dec; 17(12):917-927. PubMed ID: 31829045
[No Abstract] [Full Text] [Related]
11. Incidence and risk of proteinuria with aflibercept in cancer patients: a meta-analysis.
Peng L; Zhao Q; Ye X; Zhou Y; Hu D; Zheng S
PLoS One; 2014; 9(11):e111839. PubMed ID: 25365378
[TBL] [Abstract][Full Text] [Related]
12. Incidence and risk of hypertension associated with ramucirumab in cancer patients: A systematic review and meta-analysis.
Qi WX; Fu S; Zhang Q; Guo XM
J Cancer Res Ther; 2016; 12(2):775-81. PubMed ID: 27461650
[TBL] [Abstract][Full Text] [Related]
13. Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors.
Schutz FA; Je Y; Richards CJ; Choueiri TK
J Clin Oncol; 2012 Mar; 30(8):871-7. PubMed ID: 22312105
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab increases the risk of infections in cancer patients: A systematic review and pooled analysis of 41 randomized controlled trials.
Qi WX; Fu S; Zhang Q; Guo XM
Crit Rev Oncol Hematol; 2015 Jun; 94(3):323-36. PubMed ID: 25749417
[TBL] [Abstract][Full Text] [Related]
15. Incidence and relative risk of hemorrhagic events associated with ramucirumab in cancer patients: a systematic review and meta-analysis.
Tian R; Yan H; Zhang F; Sun P; Zheng X; Zhu Y; Wang Q; He J
Oncotarget; 2016 Oct; 7(40):66182-66191. PubMed ID: 27507055
[TBL] [Abstract][Full Text] [Related]
16. Risk of hypertension in cancer patients treated with aflibercept: a systematic review and meta-analysis.
Qi WX; Shen Z; Tang LN; Yao Y
Clin Drug Investig; 2014 Apr; 34(4):231-40. PubMed ID: 24493142
[TBL] [Abstract][Full Text] [Related]
17. Comparative evaluation of cardiovascular risks among nine FDA-approved VEGFR-TKIs in patients with solid tumors: a Bayesian network analysis of randomized controlled trials.
Hou W; Ding M; Li X; Zhou X; Zhu Q; Varela-Ramirez A; Yi C
J Cancer Res Clin Oncol; 2021 Aug; 147(8):2407-2420. PubMed ID: 33725154
[TBL] [Abstract][Full Text] [Related]
18. Hematologic toxicity assessment in solid tumor patients treated with cetuximab: a pooled analysis of 18 randomized controlled trials.
Cui R; Chu L; Liu ZQ; Xiao YY; Zhu XL; Chen YJ; Xu Q
Int J Cancer; 2015 Feb; 136(4):936-44. PubMed ID: 24975040
[TBL] [Abstract][Full Text] [Related]
19. Risk of cardiovascular adverse events in patients with solid tumors treated with ramucirumab: A meta analysis and summary of other VEGF targeted agents.
Abdel-Rahman O; ElHalawani H
Crit Rev Oncol Hematol; 2016 Jun; 102():89-100. PubMed ID: 27129437
[TBL] [Abstract][Full Text] [Related]
20. Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials.
Ranpura V; Hapani S; Chuang J; Wu S
Acta Oncol; 2010 Apr; 49(3):287-97. PubMed ID: 20156114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
